March 29, 2019 — The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease….Original Article
FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis
